Korea Investment CORP Sells 79,643 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Key Points

• Korea Investment CORP cut its stake in Zimmer Biomet by 71.2%, selling 79,643 shares and leaving a holding of 32,146 shares worth about $3.17 million; overall, hedge funds and institutional investors own roughly 88.9% of the stock.
• Zimmer Biomet slightly beat quarterly estimates (EPS $2.42 vs. $2.38; revenue $2.24B vs. $2.22B), reported revenue up 10.9% year-over-year, and set FY2026 EPS guidance of 8.300–8.450 (street consensus ~8.22).
• The company announced a quarterly dividend of $0.24 per share (annualized $0.96, 1.0% yield; ex-dividend March 31), while analysts maintain a consensus "Hold" rating with an average target price of $106.20.

Korea Investment CORP reduced its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 71.2% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 32,146 shares of the medical equipment provider's stock after selling 79,643 shares during the quarter. Korea Investment CORP's holdings in Zimmer Biomet were worth $3,166,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Key Financial Inc grew its holdings in shares of Zimmer Biomet by 164.6% during the third quarter. Key Financial Inc now owns 262 shares of the medical equipment provider's stock valued at $26,000 after buying an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. raised its holdings in Zimmer Biomet by 66.7% in the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider's stock worth $29,000 after acquiring an additional 116 shares during the last quarter. Root Financial Partners LLC purchased a new position in Zimmer Biomet in the 3rd quarter worth approximately $31,000. Cary Street Partners Investment Advisory LLC lifted its position in Zimmer Biomet by 83.7% in the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider's stock valued at $30,000 after acquiring an additional 149 shares in the last quarter. Finally, Mather Group LLC. purchased a new stake in Zimmer Biomet during the 3rd quarter valued at $36,000. 88.89% of the stock is owned by hedge funds and other institutional investors.

Zimmer Biomet Trading Down 1.1%

Zimmer Biomet stock opened at $92.68 on Friday. Zimmer Biomet Holdings, Inc. has a 12-month low of $84.59 and a 12-month high of $114.44. The firm has a market capitalization of $18.13 billion, a price-to-earnings ratio of 26.18, a P/E/G ratio of 1.92 and a beta of 0.58. The firm has a 50 day moving average of $92.34 and a 200 day moving average of $95.38. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, beating the consensus estimate of $2.38 by $0.04. The business had revenue of $2.24 billion for the quarter, compared to the consensus estimate of $2.22 billion. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The company's revenue for the quarter was up 10.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.31 earnings per share. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. As a group, research analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be paid a dividend of $0.24 per share. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 1.0%. Zimmer Biomet's payout ratio is 27.12%.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. Wall Street Zen cut Zimmer Biomet from a "buy" rating to a "hold" rating in a research note on Saturday, February 14th. Weiss Ratings reaffirmed a "hold (c-)" rating on shares of Zimmer Biomet in a research report on Wednesday, January 21st. Wells Fargo & Company boosted their target price on Zimmer Biomet from $93.00 to $98.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 11th. UBS Group restated a "sell" rating and set a $89.00 target price on shares of Zimmer Biomet in a research note on Wednesday, February 11th. Finally, William Blair started coverage on shares of Zimmer Biomet in a report on Friday, February 20th. They set a "market perform" rating on the stock. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, ten have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average target price of $106.20.

About Zimmer Biomet

Zimmer Biomet NYSE: ZBH is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company's product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.

Want to see what other hedge funds are holding ZBH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.